Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

The CCR1 antagonist BX-471 evaluated in phase II clinical trials

June 7, 2006

FDA approves reintroduction of Tysabri

June 7, 2006

Recent patents claim new therapeutic agents for psychological disorders

June 7, 2006

Novel agents for treating neurological disorders disclosed in recent patent literature

June 7, 2006

Recent patents report novel analgesic agents

June 7, 2006

Targeting FKBP38 for neuroprotection

June 7, 2006

Treatment begins in phase III study of Dyloject for postoperative pain

June 7, 2006

New compounds for the treatment of psychiatric disorders reported

June 6, 2006

Delay to initiation of phase IIa study of MEM-3454 in Alzheimer's disease

June 6, 2006

Dosing completed in phase Ib study of AL-208 for neurodegenerative diseases

June 6, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.